Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.70 |
| ▸ | HTR2A | P28223 | 5/20 | 0.70 |
| ▸ | HTR2B | P41595 | 5/20 | 0.70 |
| ▸ | CHRNB2 | P17787 | 8/20 | 0.49 |
| ▸ | CHRNB4 | P30926 | 8/20 | 0.49 |
| ▸ | CHRNA3 | P32297 | 8/20 | 0.49 |
| ▸ | CHRNA4 | P43681 | 8/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.49 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18452164 | 0.83 | HTR2C (0.67) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL18452843 | 0.83 | HRH3 (0.62) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL13137461 | 0.83 | HRH3 (0.62) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL18453013 | 0.82 | HTR2C (1.00) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL6213136 | 0.81 | HTR2C (0.68) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL18452262 | 0.79 | HRH3 (0.66) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL18452497 | 0.79 | HTR2C (1.00) | HTR2CHTR2AHTR2BHRH3MAPT | |
| SCHEMBL18453238 | 0.77 | HTR2C (0.69) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL652146 | 0.73 | CHRNB2 (0.74) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL653914 | 0.73 | CHRNB2 (0.74) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| EP-3331886-B1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LTD (GB) | 2020-07-15 | — | — | EP | disclosed |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | INDIVIOR UK LIMITED (GB) | 2020-03-10 | — | — | US | disclosed |
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR INC. | 2019-06-27 | — | — | US | disclosed |
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR INC. | 2019-06-27 | — | — | US | disclosed |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | INDIVIOR UK LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | INDIVIOR UK LIMITED (GB) | 2019-04-30 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2018-08-09 | — | — | US | disclosed |
| EP-3331886-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | Indivior UK Limited (GB) | 2018-06-13 | — | — | EP | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
| WO-2017021920-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | INDIVIOR UK LIMITED (GB) | 2017-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194225-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | DRD3, DRD2, SLC6A3 | HTR2C 29/4885HTR2A 76/4885HTR2B 143/4885 |
| US-20180222918-A1 | DOPAMINE D3 RECEPTOR ANTAGONISTS HAVING A BICYCLO MOIETY | DRD3, DRD2, SLC6A3 | HTR2C 31/4885HTR2A 77/4885HTR2B 147/4885 |
| US-10273244-B2 | Substituted hexahydropyrrolo[3,4-b]pyrroles and hexahydrocyclopenta[c]pyrroles as dopamine receptor modulators | DRD3, DRD2, OPRD1 | HTR2C 15/4885HTR2A 43/4885HTR2B 58/4885 |
| US-10584135-B2 | Substituted 3,6-diazabicyclo[3.2.0]heptanes | DRD3, DRD2, SLC6A3 | HTR2C 10/4885HTR2A 39/4885HTR2B 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.